Table 3 Tumour stage according to neoadjuvant chemotherapy administration in patients who had received radical surgery

From: A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer

Variable No. of patients ( n =67) (%)
Pre-chemotherapy TNM
T1–2N− 5 (7.5)
T1–2N+ 4 (6.0)
T3–4N− 17 (25.4)
T3–4N+ 41 (61.2)
Post-chemotherapy TNM
T0–N0 0
T1–2N− 10 (14.9)
T1–2N+ 8 (11.9)
T3–4N− 24 (35.8)
T3–4N+ 25 (37.3)
ypTNM
T0–N0 2 (3.0)
T1–2N0 9 (13.4)
T1–2N1–3 8 (11.9)
T3–4N0 20 (29.8)
T3–4N1–3 28 (41.8)